O uso de antimicrobianos na covid-19: uma análise usando a dose diária definida

Abstract

In just over two years of the SARS-CoV-2 pandemic, more than 655 million cases of covid-19 and 6 million deaths were recorded worldwide. Even with the vaccination of the population, in some cases, disease progression, hospitalization, sepsis and secondary infections occur, making it necessary to use drugs, including antimicrobials. In this context, there has been na increase in the empirical prescription of antimicrobials with the aim of treating infections secondary to covid-19. In view of these data, the present study aims to analyze the profile of antimicrobial consumption during the SARS-CoV-2 pandemic, from May to October 2020 and 2021, in na Intensive Care Unit of a secondary public hospital from the DF. Comparing the periods in which the unit admitted exclusively patients with covid-19, it is possible to observe na increase in the consumption of vancomycin, meropenem, ertapenem and polymyxin B. In comparison, there was a reduction in the consumption of ceftriaxone, piperacillin+tazobactam, ampicillin+sulbactam and linezolid. With the advancement of the pandemic, na increase in the consumption of antimicrobials used in the treatment of infections by bactéria with high resistance tôo the ragents was found. Such a change can both cause and result from the emergence of resistant pathogens in the studied intensive care unit.